Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 3 records in total 3
    records per page

    Association of Neuronal Injury Blood SERO Marker Neurofilament light chain with mild-to-moderate COVID-19

    Authors: Markus Ameres; Susanne Brandstetter; Antoaneta A. Toncheva; Michael Kabesch; David Leppert; Jens Kuhle; Sven Wellmann

    doi:10.21203/ Date: 2020-06-11 Source: ResearchSquare

    The coronavirus disease MESHD 2019 (COVID-19) affects primarily the respiratory system but neurologic manifestations MESHD of severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) are possible. Serum SERO neurofilament light chain (sNfL) has recently been considered as a specific biomarker to quantitate neuro-axonal damage. Concentrations of sNfL were determined in a prospective cohort study of 100 health care workers (84 females TRANS, 16 males TRANS) following a COVID-19 outbreak in a large hospital by using the single molecule array (Simoa) NF-light advantage kit. Twenty eight health care workers contracted mild-to-moderate COVID-19, recovered after 1-3 weeks without hospitalization and showed no or only minor neurological symptoms such as anosmia HP, fatigue MESHD fatigue HP or headache MESHD headache HP. sNfL levels were consistently higher in older persons and multivariable linear regression analysis revealed COVID-19 status as an independent predictor of sNfL (p=.005). In conclusion, increased sNfL levels in mild-to-moderate COVID-19 patients points towards a more general neuro-destructive capability of SARS-CoV-2.

    Acute encephalopathy HP with elevated CSF inflammatory markers as the initial presentation of COVID-19.

    Authors: Shelli Farhadian; Laura R. Glick; Chantal B.F. Vogels; Jared Thomas; Jennifer Chiarella; Arnau Casanovas-Massana; Jing Zhou; Camila Odio; Pavithra Vijayakumar; Bertie Geng; John Fournier; Santos Bermejo; Joseph R. Fauver; Tara Alpert; Anne L. Wyllie; Cynthia Turcotte; Matthew Steinle; Patrick Paczkowski; Charles Dela Cruz; Craig Wilen; Albert I. Ko; Sean MacKay; Nathan D. Grubaugh; Serena Spudich; Lydia Aoun Barakat

    doi:10.21203/ Date: 2020-05-11 Source: ResearchSquare

    Background: COVID-19 is caused by the severe acute respiratory syndrome MESHD virus SARS-CoV-2. It is widely recognized as a respiratory pathogen, but neurologic complications can be the presenting manifestation in a subset of infected patients. Case presentation: We describe a 78-year old immunocompromised woman who presented with altered mental status after witnessed seizure MESHD seizure HP-like activity at home. She was found to have SARS-CoV-2 infection MESHD and associated neuroinflammation. In this case, we undertake the first detailed analysis of cerebrospinal fluid (CSF) cytokines during COVID-19 infection MESHD and find a unique pattern of inflammation MESHD in CSF, but no evidence of viral neuroinvasion. Conclusion: Our findings suggest that neurologic symptoms such as encephalopathy HP and seizures MESHD seizures HP may be the initial presentation of COVID-19.  Central nervous system inflammation MESHD may associate with neurologic manifestations MESHD of disease MESHD.

    Exploring the clinical association between neurological symptoms and COVID-19 pandemic outbreak: A systematic review of current Literature

    Authors: Davide Tiziano Di Carlo; Nicola Montemurro; Giandomenico Petrella; Gabriele; Roberto Ceravolo; Paolo Perrini

    doi:10.21203/ Date: 2020-05-05 Source: ResearchSquare

    Object: The novel severe acute respiratory syndrome MESHD (SARS)-CoV-2 outbreak has been declared a pandemic in March, 2020. An increasing body of evidence suggests that patients with the coronavirus disease MESHD (COVID-19) might have a heterogeneous spectrum of neurological symptomsMethods. A systematic search of two databases was performed for studies published up to April 17th, 2020. PRISMA guidelines were followed.Results: We included 13 studies evaluating 2499 patients with laboratory-confirmed COVID-19 infections MESHD. The median age TRANS of patients was 50.3 (IQR 9.6), and the rate of male TRANS patients was 50% (95% CI 47.9-52%). The most common reported comorbidities were hypertension MESHD hypertension HP and diabetes (18.7%, 95% CI 16.9-20.7% and 9%, 95% CI 7.4-11.3%, respectively). Headache MESHD Headache HP was reported in 17.9% of patients (95% CI 16.1-19.8%), and dizziness MESHD in 13.9% (95% CI 10.7-18%). Fatigue MESHD Fatigue HP or myalgia MESHD myalgia HP, hypo/ anosmia HP, and gustatory dysfunction were reported in 24%, 55.2%, and 55.4%, of patients, respectively.Conclusions: These data support accumulating evidence that a significant proportion of patients with COVID-19 infection MESHD develop neurological manifestations, especially olfactory and gustatory dysfunction. The pathophysiology of this association is under investigation and warrants additional studies, Physicians should be aware of this possible association because during the epidemic period of COVID-19, early recognition of neurologic manifestations MESHD otherwise not explained would raise the suspect of acute respiratory syndrome MESHD coronavirus 2 infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.